Table 5.

Outcomes at end of study.^* Values are numbers (%) of group (mortality) or numbers (%) who completed follow up examination and did not have the outcome at baseline (all other outcomes)

	No (%) in structured care group	No (%) in routine care group	P value†
Primary outcomes:
Overall mortality	216/649 (33.3)	208/614 (33.9)	0.82
Diabetic retinopathy	43/359 (12.0)	45/330 (13.6)	0.55
Urinary albumin ⩾15 mg/l	56/249 (22.5)	72/234 (30.8)	0.04
Myocardial infarction	15/437 (3.4)	18/393 (4.6)	0.40
Stroke	18/446 (4.0)	16/405 (4.0)	0.95
Secondary outcomes:
Peripheral neuropathy	69/375 (18.4)	69/329 (21.0)	0.41
Angina pectoris	22/371 (5.9)	23/346 (6.7)	0.68
Intermittent claudication	13/382 (3.4)	13/374 (3.5)	0.96
Amputation	2/459 (0.44)	4/414 (0.97)	0.35

^*Median follow up period for structured care group was 7.41 years for mortality and 5.75 years for other outcomes; median follow up for routine care group was 7.32 years and 5.86 years, respectively. 

^†Wald test. As there are five outcomes we accepted P<0.01 as significant.